# Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs

> **NCT03706898** · PHASE1 · COMPLETED · sponsor: **Viriom** · enrollment: 36 (actual)

## Conditions studied

- HIV-1-infection
- Hepatic Impairment

## Interventions

- **DRUG:** Elpida®
- **DRUG:** Dolutegravir
- **DRUG:** Sofosbuvir
- **DRUG:** Daclatasvir

## Key facts

- **NCT ID:** NCT03706898
- **Lead sponsor:** Viriom
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2019-04-10
- **Final completion:** 2019-04-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03706898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03706898, "Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03706898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*